ArticlePharmacotherapy2026
User Beware: Inaccuracy and Inconsistency of Large Language Models in Providing Precision Dosing Recommendations for Patients With Kidney Impairment-A Case Series.
Article in Pharmacotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionEvidence-based dosing guidance for medications in critically ill patients with acute kidney injury (AKI) and receiving continuous kidney replacement therapy (CKRT) is limited. Freely available large language models (LLMs) can generate confident, human-like outputs. The accuracy and reproducibility of LLMs in providing precision drug dosing recommendations in the setting of AKI and CKRT have not been evaluated.
objectivesWe sought to characterize literature concordance and internal consistency of LLM-generated dosing recommendations for cefepime and meropenem in patients with AKI and receiving CKRT.
methodsSix investigators queried the freely available versions of six LLMs (ChatGPT, Claude, Google Gemini, Microsoft Copilot, OpenEvidence, and Perplexity) from July to September 2025 using three standardized vignettes asking for dosing recommendations and rationale to meet prespecified pharmacodynamic targets: (i) adult with AKI not on dialysis receiving cefepime, (ii) child receiving CKRT and cefepime, and (iii) toddler receiving high-effluent CKRT and meropenem. To assess inter-iteration consistency, each investigator also prompted one LLM three times for each vignette. Responses were parsed for concordance with recommendations in primary literature. LLM "reasoning" was evaluated for use of pharmacokinetic (PK) equations, citation accuracy versus confabulation, acknowledgment of uncertainty, and recommendations for therapeutic drug monitoring (TDM) for efficacy or safety.
resultsLLM-generated dosing recommendations varied widely. Mean concordance with literature-based recommendations was 63% (range: 28%-94%). LLMs produced variable responses to the same user upon multiple iterations, with variance in daily maintenance doses recommended ranging from 0 to 1000%. OpenEvidence universally cited relevant sources, whereas other LLMs leveraged sources inconsistently or confabulated them. Each recommended TDM, though only Claude consistently acknowledged its own uncertainty.
conclusionFreely available LLMs produce highly variable and often discordant antibiotic dosing recommendations for patients with AKI and receiving CKRT. Although valuable for hypothesis generation and literature retrieval, LLM outputs should not be used in isolation for drug dosing in critically ill patients with kidney dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.